XNYS 04 May, 2026 12:37 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Steven H. Collis | Director | Grant, award, or other acquisition of securities at price $ 15.90 per share. | 30 Apr 2026 | 1,415 | 26,161 | - | 15.9 | 22,499 | Common Shares, No Par Value |
| Russel C. Robertson | Director | Grant, award, or other acquisition of securities at price $ 15.90 per share. | 30 Apr 2026 | 1,611 | 78,418 | - | 15.9 | 25,615 | Common Shares, No Par Value |
| John A. Paulson | Director | Grant, award, or other acquisition of securities at price $ 15.90 per share. | 30 Apr 2026 | 1,375 | 73,981 | - | 15.9 | 21,863 | Common Shares, No Par Value |
| Eduardo C. Alfonso | Director | Grant, award, or other acquisition of securities at price $ 15.90 per share. | 30 Apr 2026 | 1,375 | 15,230 | - | 15.9 | 21,863 | Common Shares, No Par Value |
| Andrew J. Stewart | President, GPIC | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.82 per share. | 24 Apr 2026 | 4,216 | 86,433 | - | 15.8 | 66,697 | Common Shares, No Par Value |
| Brenton L. Saunders | Director, CEO and Chairman of the Board | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2026 | 14,700 | 981,275 | - | 0 | Common Shares, No Par Value | |
| Brenton L. Saunders | Director, CEO and Chairman of the Board | Purchase of securities on an exchange or from another person at price $ 17.14 per share. | 06 Mar 2026 | 14,700 | 966,575 | - | 17.1 | 251,958 | Common Shares, No Par Value |
| Sam A. Eldessouky | EVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2026 | 4,000 | 407,130 | - | 0 | Common Shares, No Par Value | |
| Sam A. Eldessouky | EVP and CFO | Purchase of securities on an exchange or from another person at price $ 17.13 per share. | 06 Mar 2026 | 4,000 | 403,130 | - | 17.1 | 68,520 | Common Shares, No Par Value |
| Thomas W. Ross | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2026 | 4,500 | 69,391 | - | 0 | Common Shares, No Par Value | |
| Thomas W. Ross | Director | Purchase of securities on an exchange or from another person at price $ 17.68 per share. | 03 Mar 2026 | 4,500 | 64,891 | - | 17.7 | 79,556 | Common Shares, No Par Value |
| Eduardo C. Alfonso | Director | Purchase of securities on an exchange or from another person at price $ 17.90 per share. | 02 Mar 2026 | 4,300 | 9,555 | - | 17.9 | 76,970 | Common Shares, No Par Value |
| Eduardo C. Alfonso | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2026 | 4,300 | 13,855 | - | 0 | Common Shares, No Par Value | |
| Andrew C. von Eschenbach | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2026 | 4,364 | 70,814 | - | 0 | Common Shares, No Par Value | |
| Andrew C. von Eschenbach | Director | Purchase of securities on an exchange or from another person at price $ 18.30 per share. | 27 Feb 2026 | 4,364 | 66,450 | - | 18.3 | 79,883 | Common Shares, No Par Value |
| Brenton L. Saunders | Director, CEO and Chairman of the Board | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.49 per share. | 26 Feb 2026 | 22,059 | 976,524 | - | 18.5 | 407,871 | Common Shares, No Par Value |
| Brenton L. Saunders | Director, CEO and Chairman of the Board | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.30 per share. | 26 Feb 2026 | 24,649 | 951,875 | - | 18.3 | 451,077 | Common Shares, No Par Value |
| Sam A. Eldessouky | EVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.30 per share. | 26 Feb 2026 | 15,507 | 450,600 | - | 18.3 | 283,778 | Common Shares, No Par Value |
| Sam A. Eldessouky | EVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.49 per share. | 26 Feb 2026 | 7,062 | 466,107 | - | 18.5 | 130,576 | Common Shares, No Par Value |
| Sam A. Eldessouky | EVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.30 per share. | 26 Feb 2026 | 51,470 | 399,130 | - | 18.3 | 941,901 | Common Shares, No Par Value |
| Frederick J. Munsch | SVP, Controller and CAO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.30 per share. | 26 Feb 2026 | 2,437 | 104,005 | - | 18.3 | 44,597 | Common Shares, No Par Value |
| Frederick J. Munsch | SVP, Controller and CAO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.30 per share. | 26 Feb 2026 | 5,692 | 98,313 | - | 18.3 | 104,164 | Common Shares, No Par Value |
| Frederick J. Munsch | SVP, Controller and CAO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.49 per share. | 26 Feb 2026 | 2,042 | 106,442 | - | 18.5 | 37,757 | Common Shares, No Par Value |
| Yehia Hashad | EVP of R&D and CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.30 per share. | 26 Feb 2026 | 11,621 | 180,041 | - | 18.3 | 212,664 | Common Shares, No Par Value |
| Yehia Hashad | EVP of R&D and CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.49 per share. | 26 Feb 2026 | 2,169 | 196,737 | - | 18.5 | 40,105 | Common Shares, No Par Value |
| Yehia Hashad | EVP of R&D and CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.30 per share. | 26 Feb 2026 | 5,075 | 191,662 | - | 18.3 | 92,873 | Common Shares, No Par Value |
| Andrew J. Stewart | President, GPIC | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.30 per share. | 26 Feb 2026 | 2,007 | 90,649 | - | 18.3 | 36,728 | Common Shares, No Par Value |
| Andrew J. Stewart | President, GPIC | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.49 per share. | 26 Feb 2026 | 2,984 | 92,656 | - | 18.5 | 55,174 | Common Shares, No Par Value |
| Luc Bonnefoy | President, Surgical | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.30 per share. | 26 Feb 2026 | 9,221 | 100,001 | - | 18.3 | 168,744 | Common Shares, No Par Value |
| Luc Bonnefoy | President, Surgical | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.49 per share. | 26 Feb 2026 | 4,404 | 113,533 | - | 18.5 | 81,430 | Common Shares, No Par Value |
| Luc Bonnefoy | President, Surgical | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.30 per share. | 26 Feb 2026 | 4,311 | 109,222 | - | 18.3 | 78,891 | Common Shares, No Par Value |
| Brenton L. Saunders | Director, CEO and Chairman of the Board | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2026 | 327,102 | 998,583 | - | 0 | Common Shares, No Par Value | |
| Sam A. Eldessouky | EVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2026 | 81,775 | 473,169 | - | 0 | Common Shares, No Par Value | |
| Frederick J. Munsch | SVP, Controller and CAO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2026 | 18,253 | 108,484 | - | 0 | Common Shares, No Par Value | |
| Yehia Hashad | EVP of R&D and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2026 | 35,046 | 198,906 | - | 0 | Common Shares, No Par Value | |
| Andrew J. Stewart | President, GPIC | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2026 | 32,710 | 95,640 | - | 0 | Common Shares, No Par Value | |
| Luc Bonnefoy | President, Surgical | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2026 | 30,373 | 117,937 | - | 0 | Common Shares, No Par Value | |
| Steven H. Collis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2026 | 4,491 | 24,746 | - | 0 | Common Shares, No Par Value | |
| Steven H. Collis | Director | Purchase of securities on an exchange or from another person at price $ 17.81 per share. | 23 Feb 2026 | 15,000 | 20,255 | - | 17.8 | 267,150 | Common Shares, No Par Value |
| Brenton L. Saunders | Director, CEO and Chairman of the Board | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.99 per share. | 23 Feb 2026 | 65,444 | 671,481 | - | 18.0 | 1,177,338 | Common Shares, No Par Value |
| Russel C. Robertson | Director | Purchase of securities on an exchange or from another person at price $ 17.90 per share. | 20 Feb 2026 | 4,400 | 72,407 | - | 17.9 | 78,760 | Common Shares, No Par Value |
| Russel C. Robertson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2026 | 4,400 | 76,807 | - | 0 | Common Shares, No Par Value | |
| Steven H. Collis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2026 | 5,255 | 5,255 | - | 0 | Common Shares, No Par Value | |
| Russel C. Robertson | Director | Grant, award, or other acquisition of securities at price $ 17.65 per share. | 19 Feb 2026 | 1,451 | 68,007 | - | 17.6 | 25,610 | Common Shares, No Par Value |
| Karen L. Ling | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2026 | 4,000 | 45,676 | - | 0 | Common Shares, No Par Value | |
| Karen L. Ling | Director | Purchase of securities on an exchange or from another person at price $ 17.74 per share. | 19 Feb 2026 | 4,000 | 41,676 | - | 17.7 | 70,968 | Common Shares, No Par Value |
| John A. Paulson | Director | Grant, award, or other acquisition of securities at price $ 17.65 per share. | 19 Feb 2026 | 1,239 | 72,606 | - | 17.6 | 21,868 | Common Shares, No Par Value |
| Eduardo C. Alfonso | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2026 | 5,255 | 5,255 | - | 0 | Common Shares, No Par Value | |
| Sam A. Eldessouky | EVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2026 | 70,578 | 391,394 | - | 0 | Common Shares, No Par Value | |
| Frederick J. Munsch | SVP, Controller and CAO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2026 | 12,498 | 90,231 | - | 0 | Common Shares, No Par Value | |
| Yehia Hashad | EVP of R&D and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2026 | 29,406 | 163,860 | - | 0 | Common Shares, No Par Value | |
| Luc Bonnefoy | President, Surgical | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2026 | 10,202 | 87,564 | - | 0 | Common Shares, No Par Value | |
| Russel C. Robertson | Director | Grant, award, or other acquisition of securities at price $ 15.60 per share. | 14 Nov 2025 | 1,642 | 66,556 | - | 15.6 | 25,615 | Common Shares, No Par Value |
| John A. Paulson | Director | Grant, award, or other acquisition of securities at price $ 15.60 per share. | 14 Nov 2025 | 1,402 | 71,367 | - | 15.6 | 21,871 | Common Shares, No Par Value |
| Brenton L. Saunders | Director, CEO and Chairman of the Board | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.44 per share. | 05 Aug 2025 | 4,231 | 736,925 | - | 14.4 | 61,096 | Common Shares, No Par Value |
| Sam A. Eldessouky | EVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Aug 2025 | 42,517 | 320,816 | - | 0 | Common Shares, No Par Value | |
| Frederick J. Munsch | SVP, Controller and CAO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Aug 2025 | 7,529 | 77,733 | - | 0 | Common Shares, No Par Value | |
| Yehia Hashad | EVP of R&D and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Aug 2025 | 17,715 | 134,454 | - | 0 | Common Shares, No Par Value | |
| Luc Bonnefoy | President, Surgical | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Aug 2025 | 6,146 | 77,362 | - | 0 | Common Shares, No Par Value | |
| Sam A. Eldessouky | EVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.32 per share. | 25 Jul 2025 | 3,996 | 278,299 | - | 14.3 | 57,223 | Common Shares, No Par Value |
| Frederick J. Munsch | SVP, Controller and CAO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.32 per share. | 25 Jul 2025 | 1,090 | 70,204 | - | 14.3 | 15,609 | Common Shares, No Par Value |
| Yehia Hashad | EVP of R&D and CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.32 per share. | 25 Jul 2025 | 2,841 | 116,739 | - | 14.3 | 40,683 | Common Shares, No Par Value |
| Luc Bonnefoy | President, Surgical | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.32 per share. | 25 Jul 2025 | 2,167 | 71,216 | - | 14.3 | 31,031 | Common Shares, No Par Value |
| Brenton L. Saunders | Director, CEO and Chairman of the Board | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jul 2025 | 150,000 | 900,000 | - | - | Performance Stock Units | |
| Luc Bonnefoy | President, Surgical | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.33 per share. | 13 Jun 2025 | 968 | 73,383 | - | 12.3 | 11,935 | Common Shares, No Par Value |
| Brett M. Icahn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2025 | 20,338 | 61,147 | - | 0 | Common Shares, No Par Value | |
| Russel C. Robertson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2025 | 20,338 | 64,914 | - | 0 | Common Shares, No Par Value | |
| Andrew C. von Eschenbach | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2025 | 20,338 | 62,086 | - | 0 | Common Shares, No Par Value | |
| Karen L. Ling | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2025 | 20,338 | 37,676 | - | 0 | Common Shares, No Par Value | |
| Sarah B. Kavanagh | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2025 | 20,338 | 53,699 | - | 0 | Common Shares, No Par Value | |
| Thomas W. Ross | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2025 | 20,338 | 60,391 | - | 0 | Common Shares, No Par Value | |
| John A. Paulson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2025 | 20,338 | 69,965 | - | 0 | Common Shares, No Par Value | |
| Nathalie Bernier | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2025 | 20,338 | 69,663 | - | 0 | Common Shares, No Par Value | |
| Brenton L. Saunders | Director, CEO and Chairman of the Board | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2025 | 22,000 | 741,156 | - | 0 | Common Shares, No Par Value | |
| Brenton L. Saunders | Director, CEO and Chairman of the Board | Purchase of securities on an exchange or from another person at price $ 11.28 per share. | 22 May 2025 | 22,000 | 719,156 | - | 11.3 | 248,072 | Common Shares, No Par Value |
| Andrew C. von Eschenbach | Director | Purchase of securities on an exchange or from another person at price $ 11.76 per share. | 02 May 2025 | 1,695 | 41,748 | - | 11.8 | 19,925 | Common Shares, No Par Value |
| Russel C. Robertson | Director | Grant, award, or other acquisition of securities at price $ 11.59 per share. | 01 May 2025 | 2,210 | 44,576 | - | 11.6 | 25,614 | Common Shares, No Par Value |
| John A. Paulson | Director | Grant, award, or other acquisition of securities at price $ 11.59 per share. | 01 May 2025 | 1,887 | 49,627 | - | 11.6 | 21,870 | Common Shares, No Par Value |
| Andrew J. Stewart | See remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.89 per share. | 24 Apr 2025 | 3,954 | 62,930 | - | 13.9 | 54,921 | Common Shares, No Par Value |
| Luc Bonnefoy | President,Surgical | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.00 per share. | 28 Feb 2025 | 1,110 | 77,380 | - | 16 | 17,760 | Common Shares, No Par Value |
| Luc Bonnefoy | President,Surgical | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.00 per share. | 28 Feb 2025 | 3,029 | 74,351 | - | 16 | 48,464 | Common Shares, No Par Value |
| Brenton L. Saunders | Director, CEO and Chairman of the Board | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2025 | 600,858 | 600,858 | - | - | Non-Qualified Stock Options (right to purchase) | |
| Brenton L. Saunders | Director, CEO and Chairman of the Board | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2025 | 168,168 | 697,156 | - | 0 | Common Shares, No Par Value | |
| Sam A. Eldessouky | EVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2025 | 141,630 | 141,630 | - | - | Non-Qualified Stock Options (right to purchase) | |
| Sam A. Eldessouky | EVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2025 | 59,459 | 282,295 | - | 0 | Common Shares, No Par Value | |
| Frederick J. Munsch | SVP, Controller and CAO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2025 | 18,581 | 71,294 | - | 0 | Common Shares, No Par Value | |
| Yehia Hashad | EVP of R&D and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2025 | 60,085 | 60,085 | - | - | Non-Qualified Stock Options (right to purchase) | |
| Yehia Hashad | EVP of R&D and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2025 | 25,225 | 119,580 | - | 0 | Common Shares, No Par Value | |
| Andrew J. Stewart | See remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2025 | 23,423 | 66,884 | - | 0 | Common Shares, No Par Value | |
| Andrew J. Stewart | See remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2025 | 55,793 | 55,793 | - | - | Non-Qualified Stock Options (right to purchase) | |
| Luc Bonnefoy | President,Surgical | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2025 | 55,793 | 55,793 | - | - | Non-Qualified Stock Options (right to purchase) | |
| Luc Bonnefoy | President,Surgical | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2025 | 23,423 | 78,490 | - | 0 | Common Shares, No Par Value | |
| Saunders L. Brenton | Director, CEO and Chairman of the Board | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.83 per share. | 23 Dec 2024 | 73,782 | 553,637 | - | 17.8 | 1,315,533 | Common Shares, No Par Value |
| Hashad Yehia | EVP of R&D and CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.83 per share. | 23 Dec 2024 | 2,751 | 94,355 | - | 17.8 | 49,050 | Common Shares, No Par Value |
| Frederick Munsch J. | SVP, Controller and CAO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.83 per share. | 23 Dec 2024 | 908 | 54,905 | - | 17.8 | 16,190 | Common Shares, No Par Value |
| A. Eldessouky Sam | EVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.83 per share. | 23 Dec 2024 | 8,582 | 222,836 | - | 17.8 | 153,017 | Common Shares, No Par Value |
| Yehia Hashad | EVP of R&D and CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.83 per share. | 23 Dec 2024 | 2,324 | 97,106 | - | 17.8 | 41,437 | Common Shares, No Par Value |
| Saunders Brenton L. | Director, CEO and Chairman of the Board | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.83 per share. | 23 Dec 2024 | 24,649 | 528,988 | - | 17.8 | 439,492 | Common Shares, No Par Value |
| Stewart Andrew J. | See remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.83 per share. | 23 Dec 2024 | 2,524 | 43,461 | - | 17.8 | 45,003 | Common Shares, No Par Value |
| Frederick J. Munsch | SVP, Controller and CAO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.83 per share. | 23 Dec 2024 | 2,192 | 52,713 | - | 17.8 | 39,083 | Common Shares, No Par Value |
| Sam A. Eldessouky | EVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.83 per share. | 23 Dec 2024 | 7,249 | 231,418 | - | 17.8 | 129,250 | Common Shares, No Par Value |
| Russel C. Robertson | Director | Grant, award, or other acquisition of securities at price $ 19.29 per share. | 30 Sep 2024 | 1,328 | 43,694 | - | 19.3 | 25,617 | Common Shares, No Par Value |
| John A. Paulson | Director | Grant, award, or other acquisition of securities at price $ 19.29 per share. | 30 Sep 2024 | 1,134 | 48,874 | - | 19.3 | 21,875 | Common Shares, No Par Value |
| Brenton L. Saunders | Director, CEO and Chairman of the Board | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Aug 2024 | 32,250 | 627,419 | - | 0 | Common Shares, No Par Value | |
| Brenton L. Saunders | Director, CEO and Chairman of the Board | Purchase of securities on an exchange or from another person at price $ 15.66 per share. | 05 Aug 2024 | 32,250 | 595,169 | - | 15.7 | 505,067 | Common Shares, No Par Value |
| Brett M. Icahn | Director | 02 Aug 2024 | 14,696 | 40,809 | - | 0 | Common Shares, No Par Value | ||
| Russel C. Robertson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Aug 2024 | 14,696 | 42,366 | - | 0 | Common Shares, No Par Value | |
| Andrew C. von Eschenbach | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Aug 2024 | 14,696 | 40,053 | - | 0 | Common Shares, No Par Value | |
| Karen L. Ling | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Aug 2024 | 14,696 | 17,338 | - | 0 | Common Shares, No Par Value | |
| Sarah B. Kavanagh | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Aug 2024 | 14,696 | 33,361 | - | 0 | Common Shares, No Par Value | |
| Thomas W. Ross | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Aug 2024 | 14,696 | 40,053 | - | 0 | Common Shares, No Par Value | |
| John A. Paulson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Aug 2024 | 14,696 | 47,740 | - | 0 | Common Shares, No Par Value | |
| Nathalie Bernier | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Aug 2024 | 14,696 | 49,325 | - | 0 | Common Shares, No Par Value | |
| Sam A. Eldessouky | EVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.53 per share. | 25 Jul 2024 | 5,113 | 238,667 | - | 15.5 | 79,405 | Common Shares, No Par Value |
| Frederick J. Munsch | SVP, Controller and CAO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.53 per share. | 25 Jul 2024 | 1,313 | 55,813 | - | 15.5 | 20,391 | Common Shares, No Par Value |
| Yehia Hashad | EVP of R&D and CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.53 per share. | 25 Jul 2024 | 2,841 | 99,430 | - | 15.5 | 44,121 | Common Shares, No Par Value |
| Luc Bonnefoy | President,Surgical | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.53 per share. | 25 Jul 2024 | 2,144 | 55,067 | - | 15.5 | 33,296 | Common Shares, No Par Value |
| Russel C. Robertson | Director | Grant, award, or other acquisition of securities at price $ 14.52 per share. | 28 Jun 2024 | 1,764 | 27,670 | - | 14.5 | 25,613 | Common Shares, No Par Value |
| John A. Paulson | Director | Grant, award, or other acquisition of securities at price $ 14.52 per share. | 28 Jun 2024 | 1,506 | 33,044 | - | 14.5 | 21,867 | Common Shares, No Par Value |
| Luc Bonnefoy | President,Surgical | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.09 per share. | 14 Jun 2024 | 958 | 57,211 | - | 15.1 | 14,456 | Common Shares, No Par Value |
| Andrew J. Stewart | See remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.90 per share. | 24 Apr 2024 | 3,943 | 45,985 | - | 14.9 | 58,751 | Common Shares, No Par Value |
| John A. Paulson | Director | Grant, award, or other acquisition of securities at price $ 17.30 per share. | 29 Mar 2024 | 1,264 | 31,538 | - | 17.3 | 21,867 | Common Shares, No Par Value |
| Russel C. Robertson | Director | Grant, award, or other acquisition of securities at price $ 17.30 per share. | 29 Mar 2024 | 1,481 | 25,906 | - | 17.3 | 25,621 | Common Shares, No Par Value |
| Karen L. Ling | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2024 | 2,642 | 2,642 | - | 0 | Common Shares, No Par Value | |
| Sam A. Eldessouky | EVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.47 per share. | 01 Mar 2024 | 4,854 | 243,780 | - | 16.5 | 79,945 | Common Shares, No Par Value |
| Frederick J. Munsch | SVP, Controller and CAO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.47 per share. | 01 Mar 2024 | 995 | 57,126 | - | 16.5 | 16,388 | Common Shares, No Par Value |
| Yehia Hashad | EVP of R&D and CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.47 per share. | 01 Mar 2024 | 2,143 | 102,271 | - | 16.5 | 35,295 | Common Shares, No Par Value |
| Luc Bonnefoy | President,Surgical | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.47 per share. | 01 Mar 2024 | 1,098 | 58,169 | - | 16.5 | 18,084 | Common Shares, No Par Value |
| L. Brenton Saunders | Director, CEO and Chair | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2024 | 187,919 | 562,919 | - | 0 | Common Shares, No Par Value | |
| Sam A. Eldessouky | EVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2024 | 152,439 | 152,439 | - | - | Non-Qualified Stock Options (right to purchase) | |
| Saunders Brenton L. | Director, CEO and Chair | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2024 | 569,105 | 569,105 | - | - | Non-Qualified Stock Options (right to purchase) | |
| Eldessouky Sam A. | EVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2024 | 50,335 | 248,634 | - | 0 | Common Shares, No Par Value | |
| Frederick J. Munsch | SVP, Controller and CAO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2024 | 18,183 | 58,121 | - | 0 | Common Shares, No Par Value | |
| Yehia Hashad | EVP of R&D and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2024 | 20,973 | 104,414 | - | 0 | Common Shares, No Par Value | |
| Yehia Hashad | EVP of R&D and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2024 | 63,516 | 63,516 | - | - | Non-Qualified Stock Options (right to purchase) | |
| Andrew J. Stewart | See remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2024 | 50,813 | 50,813 | - | - | Non-Qualified Stock Options (right to purchase) | |
| Andrew J. Stewart | See remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2024 | 16,778 | 49,928 | - | 0 | Common Shares, No Par Value | |
| Luc Bonnefoy | President,Surgical | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2024 | 16,778 | 59,267 | - | 0 | Common Shares, No Par Value | |
| Luc Bonnefoy | President,Surgical | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2024 | 50,813 | 50,813 | - | - | Non-Qualified Stock Options (right to purchase) |